BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a new class of precision immunology medicines that eliminate the disease-driving antibodies at the root of autoimmune disease.BHV-1300 targets the TSHR-IgG1 autoantibody that drives…
News provided by PR Newswire.
